Outlook Therapeutics slides on Q1 loss, FDA rejection raises cash concerns
Biotech reports negative revenue as UK returns bite, with $8.7M cash runway as it seeks fourth regulatory path for eye drug
Outlook Therapeutics shares declined on Monday after the biotechnology company reported a wider-than-expected first-quarter loss and negative revenue, underscoring mounting pressure as it seeks regulatory approval for its flagship eye treatment in the United States.
The company reported an adjusted net loss of $13.5 million, or $0.22 per share, for the fiscal quarter ended December 31, 2025, compared with an adjusted loss of $21.6 million, or $0.89 per share, in the same period last year. Including certain items, the net loss attributable to common stockholders was $23.1 million, or $0.38 per share, a significant reversal from net income of $17.4 million, or $0.72 per share, in the prior-year quarter.
Revenue came in at negative $1.2 million, impacted by an increased returns reserve for product returns from the company's UK distributor. Outlook Therapeutics said it does not anticipate further adjustments for these specific batches in fiscal year 2026.
The financial results arrive as the company confronts its third regulatory setback for ONS-5010 (LYTENAVA), its bevacizumab-vikg treatment for wet age-related macular degeneration. The U.S. Food and Drug Administration issued a Complete Response Letter on December 30, 2025, citing a single deficiency: a purported lack of substantial evidence of effectiveness and recommending additional confirmatory evidence.
Outlook Therapeutics submitted a Type A meeting request to the FDA on February 11, 2026 to discuss the path forward. The company said the determination was inconsistent with the totality of evidence submitted in its Biologics License Application and was unexpected following prior discussions with the agency in September 2025, when it believed it had aligned on resubmission requirements. The FDA has not expressed any safety concerns with ONS-5010.
The regulatory challenges are compounded by mounting liquidity pressures. Cash and cash equivalents stood at $8.7 million as of December 31, 2025, though the company noted it received an additional $2.4 million in net proceeds from its at-the-market offering program after quarter-end. With a market capitalization of approximately $36 million and a negative book value of $0.60 per share, the company's financial runway has become an increasing concern for investors.
Despite the domestic headwinds, the company highlighted progress in European markets. LYTENAVA unit sales in Europe more than doubled quarter-over-quarter, with Austria launching in January 2026. Additional European launches are planned for Ireland and the Netherlands in 2026, followed by France, Italy, and Spain in 2027. The company is also pursuing partnerships in Latin America and Asia.
Analysts maintain a price target of $5.38 on the stock, according to market data, representing significant upside from current levels but contingent on resolving the FDA impasse and securing additional financing to sustain operations through the regulatory process.
The Type A meeting with the FDA represents a critical juncture for Outlook Therapeutics. The company said it conducted informal discussions with the agency prior to submitting the formal meeting request and remains confident its clinical evidence meets the FDA's substantial evidence standard. However, with limited cash resources and a history of regulatory rejections, investors await clarity on both the regulatory path and the company's funding strategy.